Unipi Team Leader: prof. Piero Marchetti, Dip. di Medicina Clinica e Sperimentale
INNODIA is a global partnership between 26 academic institutions, 4 industrial partners, a small sized enterprise and 2 patient organisations, bringing their knowledge and experience together with one common goal: "To fight type 1 diabetes".
Preclinical type 1 diabetes (T1D) research has made important advances in recent years, but less progress has been made in translating findings from in vitro and animal models into effective clinical interventions. INNODIA aims to achieve a break-through in the way in which we study T1D to enable us to move closer towards prevention and cure of T1D.
INNODIA will collect throughout Europe blood samples and data from newly diagnosed patients with type 1 diabetes and their first degree relatives as to study the evolution of the disease in these individuals and develop new ways to predict the risk for relatives for developing the disease and eventually find a cure for those already diagnosed with the disease.
Novel research tools, making use of advanced technologies, already available or under development in the different academic partner institutes and pharmaceutical company , will be applied and aim to result in the identification of new disease biomarkers to predict the individual risk for relatives to develop the disease. Also, these biomarkers, which are factors that can be measured in the blood of each individual, may lead to the design of better and more personalized therapies.
Coordinator
KATHOLIEKE UNIVERSITEIT LEUVEN Belgium
Participants
- THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE United Kingdom
- MEDIZINISCHE UNIVERSITAT GRAZ Austria
- UNIVERSITE LIBRE DE BRUXELLES Belgium
- KOBENHAVNS UNIVERSITET Denmark
- REGION HOVEDSTADENDenmark
- INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE France
- HELSINGIN YLIOPISTO Finland
- OULUN YLIOPISTO Finland
- TURUN YLIOPISTO Finland
- Hannoversche Kinderheilanstalt Germany
- HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH Germany
- TECHNISCHE UNIVERSITAET DRESDEN Germany
- UNIVERSITAET ULM Germany
- UNIVERSITA' DEGLI STUDI DI SIENA Italy
- UNIVERSITA DEGLI STUDI GABRIELE D'ANNUNZIO DI CHIETI-PESCARA Italy
- UNIVERSITA DI PISA Italy
- CENTRE HOSPITALIER DE LUXEMBOURG Luxembourg
- UNIVERSITETET I OSLO Norway
- SLASKI UNIWERSYTET MEDYCZNY W KATOWICACH Poland
- UNIVERZA V LJUBLJANI Slovenia
- UNIVERSITE DE LAUSANNE Switzerland
- STICHTING KATHOLIEKE UNIVERSITEIT Netherlands
- ACADEMISCH ZIEKENHUIS LEIDEN Netherlands
- KING'S COLLEGE LONDON United Kingdom
- MEDICAL RESEARCH COUNCIL United Kingdom
- UNIVERCELL BIOSOLUTIONS SAS France
- SANOFI-AVENTIS DEUTSCHLAND GMBH Germany
- NOVO NORDISK A/S Denmark
- GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. United Kingdom
- Eli Lilly and Company Limited United Kingdom
- JDRF INTERNATIONAL United States
- THE LEONA M. AND HARRY B. HELMSLEY CHARITABLE TRUST United States
- OSLO UNIVERSITETSSYKEHUS HF Norway
Start date 01/11/2015
End date 31/10/2022
Duration 84 months
Project cost 36.665.442 €
Project funding 17.629.999 €
Unipi quota 423.000 €
Call title H2020-JTI-IMI2-2014-01-two-stage
Unipi role Participant
Project website: https://www.innodia.eu/